Abstract
Genomic studies revealed two main components in the genetic architecture of schizophrenia, one constituted by common variants determining a distributed polygenic effect and one represented by a large number of heterogeneous rare and highly disruptive mutations. These gene modifications often affect neural transmission and different studies proved an involvement of metabotropic glutamate receptors in schizophrenia phenotype. Through the combination of literature information with genomic data from public repositories, we analyzed the current knowledge on the involvement of genetic variations of the human metabotropic glutamate receptors in schizophrenia and related endophenotypes. Despite the analysis did not reveal a definitive connection, different suggestive associations have been identified and in particular a relevant role has emerged for GRM3 in affecting specific schizophrenia endophenotypes. This supports the hypothesis that these receptors are directly involved in schizophrenia disorder.
Keywords: Metabotropic glutamate receptors, schizophrenia, antipsychotic drugs, gene variants, omics data, bioinformatics.
Graphical Abstract
Current Neuropharmacology
Title:The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia
Volume: 14 Issue: 5
Author(s): Carlo Maj, Alessandra Minelli, Edoardo Giacopuzzi, Emilio Sacchetti and Massimo Gennarelli
Affiliation:
Keywords: Metabotropic glutamate receptors, schizophrenia, antipsychotic drugs, gene variants, omics data, bioinformatics.
Abstract: Genomic studies revealed two main components in the genetic architecture of schizophrenia, one constituted by common variants determining a distributed polygenic effect and one represented by a large number of heterogeneous rare and highly disruptive mutations. These gene modifications often affect neural transmission and different studies proved an involvement of metabotropic glutamate receptors in schizophrenia phenotype. Through the combination of literature information with genomic data from public repositories, we analyzed the current knowledge on the involvement of genetic variations of the human metabotropic glutamate receptors in schizophrenia and related endophenotypes. Despite the analysis did not reveal a definitive connection, different suggestive associations have been identified and in particular a relevant role has emerged for GRM3 in affecting specific schizophrenia endophenotypes. This supports the hypothesis that these receptors are directly involved in schizophrenia disorder.
Export Options
About this article
Cite this article as:
Maj Carlo, Minelli Alessandra, Giacopuzzi Edoardo, Sacchetti Emilio and Gennarelli Massimo, The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia, Current Neuropharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570159X13666150514232745
DOI https://dx.doi.org/10.2174/1570159X13666150514232745 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets The Promotional Effect of Mesenchymal Stem Cell Homing on Bone Tissue Regeneration
Current Stem Cell Research & Therapy Neuroactive Molecules in the Brains of Nonhuman Primates and Their Therapeutic Application to Neurodegenerative Disorders
Central Nervous System Agents in Medicinal Chemistry Synthesis of Novel N-Substituted Tetrazolonaphthalenes: Agomelatin Analogs
Letters in Organic Chemistry A Pilot Study on Prostate Cancer Risk and Pro-Inflammatory Genotypes: Pathophysiology and Therapeutic Implications
Current Pharmaceutical Design The Use of Major Analgesics in Patients with Renal Dysfunction
Current Drug Targets A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Pleasure as an Overlooked Target of Substance Use Disorder Research and Treatment
Current Drug Abuse Reviews Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract
Current Molecular Pharmacology Biological Function and Mechanism of Bone Marrow Mesenchymal Stem Cells-packed Poly (3,4-ethylenedioxythiophene) (PEDOT) Scaffolds for Peripheral Nerve Injury: The Involvement of miR-21-Notch Signaling Pathway
Current Neurovascular Research The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology The Effects of Testosterone Supplementation on Cognitive Functioning in Older Men.
CNS & Neurological Disorders - Drug Targets PLGA Nanoparticles and Polysorbate-80-Coated PLGA Nanoparticles Increase the In vitro Antioxidant Activity of Melatonin
Current Drug Delivery Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Effects of Galantamine in Alzheimers Disease: Double-blind Withdrawal Studies Evaluating Sustained Versus Interrupted Treatment
Current Alzheimer Research Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Adverse Drug Reaction Labelling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for Oral Formulations in Australia, Denmark and the United States
Current Drug Safety